Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miricorilant Bioavailability Study in Healthy Subjects
NCT07240116Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of miricorilant (7 arms), sponsored by Corcept Therapeutics. Primary endpoints: Time of Maximum Observed Concentration, Maximum Observed Concentration and 7 more. Started Sep 2025; status: completed.
02
Drugs
miricorilant
Beyond the preview
Go deeper on NCT07240116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240116.